News/ News/ R&D Amid crowded migraine market, Lundbeck goes its own way Phil Taylor CGRP, Lundbeck, migraine, PACAP, Vyepti 0 Comment The market for migraine treatment and prevention has been transformed by the launch of several new drugs targeting Share X Amid crowded migraine market, Lundbeck goes its own way https://pharmaphorum.com/news/amid-crowded-migraine-market-lundbeck-goes-its-own-way/
Market Access/ News/ News FDA approves ‘potential blockbuster’ migraine jab from Lundbeck Richard Staines Allergan, Amgen, Eli Lilly, Lundbeck, migraine, neurology, Novartis, Teva, Vyepti 0 Comment The FDA has approved Lundbeck’s eptinezumab prophylactic treatment for migraine, the last from a gang of four drugs Share X FDA approves ‘potential blockbuster’ migraine jab from Lundbeck https://pharmaphorum.com/news/fda-approves-potential-blockbuster-migraine-jab-from-lundbeck/
